Regorafenib
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Regorafenib |
| DrugBank ID | DB08896 |
| Brand Names (EU) | Stivarga |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.76% |
Approved Indication (EMA)
Stivarga is indicated as monotherapy for the treatment of adult patients with: metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy; unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib; hepatocellular carcinoma (HCC) who hav
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | liposarcoma | 99.76% | DL |
| 2 | ovarian myxoid liposarcoma | 99.68% | DL |
| 3 | clear cell renal carcinoma | 99.47% | DL |
| 4 | renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions | 99.24% | DL |
| 5 | unclassified renal cell carcinoma | 99.24% | DL |
| 6 | renal cell carcinoma associated with neuroblastoma | 99.24% | DL |
| 7 | childhood kidney cell carcinoma | 99.07% | DL |
| 8 | vulva sarcoma | 99.06% | DL |
| 9 | spindle cell liposarcoma | 98.85% | DL |
| 10 | adenocarcinoma of liver and intrahepatic biliary tract | 98.76% | DL |
| 11 | undifferentiated carcinoma of liver and intrahepatic biliary tract | 98.74% | DL |
| 12 | renal cell carcinoma (disease) | 98.67% | DL |
| 13 | renal carcinoma | 98.61% | DL |
| 14 | angiolipoma | 98.60% | DL |
| 15 | amyotrophic lateral sclerosis | 98.52% | DL |
| 16 | extrahepatic bile duct adenocarcinoma | 98.45% | DL |
| 17 | amyotrohpic lateral sclerosis type 22 | 98.40% | DL |
| 18 | breast fibroadenoma | 98.38% | DL |
| 19 | amyotrophic lateral sclerosis, susceptibility to | 98.37% | DL |
| 20 | pleomorphic adenoma | 98.35% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.